Structure-based virtual screening of 3957 drug-like compounds from DrugBank identified three top-ranking FDA-approved candidates (DB16703, DB08512, and DB16047) with strong binding affinity across the three selected AML targets: LSD1, BCL2, and mutant IDH1 (R132H). The gene discussed is BCL2; the disease is acute myeloid leukemia.